A Study on the Regulation of Gene Therapy

碩士 === 嶺東科技大學 === 財經法律研究所 === 100 === Abstract Gene therapy, the insertion of genes into an individual's cells and tissues to treat a disease, is notably absent from the litigations identified in the study. This is not surprising, because up until now human gene therapy has failed for the most...

Full description

Bibliographic Details
Main Authors: CHEN,YUNG-CHEN, 陳永震
Other Authors: 黃承啟
Format: Others
Language:zh-TW
Published: 2011
Online Access:http://ndltd.ncl.edu.tw/handle/47040743005884790016
id ndltd-TW-100LTC00308002
record_format oai_dc
spelling ndltd-TW-100LTC003080022015-10-13T20:46:56Z http://ndltd.ncl.edu.tw/handle/47040743005884790016 A Study on the Regulation of Gene Therapy 基因治療法制化之研究 CHEN,YUNG-CHEN 陳永震 碩士 嶺東科技大學 財經法律研究所 100 Abstract Gene therapy, the insertion of genes into an individual's cells and tissues to treat a disease, is notably absent from the litigations identified in the study. This is not surprising, because up until now human gene therapy has failed for the most part to progress beyond the clinical testing stage. However, there is great hope that ultimately gene therapy will prove a powerful new form of treatment, and when that occurs it could result in a new category of human gene patent litigation. It is important to bear in mind that the mere perception of a threat of litigation could alter the course of research and the commercialization of biomedical technology, so it would be a mistake to assume that litigation tells the whole story on the impact of human gene patents. But perceived threats could be overblown, and litigation does provide some a publicly accessible source data from which to objective assess the effect of these patents on innovation. The high degree of concern that has been expressed regarding the perceived detrimental impact of human gene patents on research and medicine is not reflected in the litigation history of these patents. To date, these patents do not appear to have been enforced in a manner that would warrant enactment of legislation to ban the patenting of DNA and DNA-based inventions. Many of the attacks on gene patents assume that the overall cost of these patents to society exceeds any positive benefit. However, the critics often fail to account for the positive benefits of human gene patents, particularly in the protection of therapeutic proteins, but perhaps even in incentivizing the discovery and commercialization of research tools and genetic diagnostics. Any appraisal of the patent system that focuses solely on the patents right to exclude will naturally lead to a conclusion that patents are a detriment to society, but such an analysis is flawed for failing to account for the substantial benefits to be derived from the patents ability to incentivize research and innovation. The newest and next frontier in the battle against doping in sports targets gene doping Gene therapy is a nascent medical field that refers to the insertion of a new gene - a functional one - into human cells to correct the DNA for some defective, malfunctioning, or absent gene This can be facilitated by introducing a virus into the cells through injection or delivery to the lungs by aerosol. Sometimes, cells are removed from the body, treated outside the body in a lab, and then reintroduced into the body. Gene therapy has shown promise in patients with immuno-deficiencies or hemophili Researchers are developing pharmaceuticals that can switch on the genes responsible for protein synthesis as well. 黃承啟 2011 學位論文 ; thesis 172 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 嶺東科技大學 === 財經法律研究所 === 100 === Abstract Gene therapy, the insertion of genes into an individual's cells and tissues to treat a disease, is notably absent from the litigations identified in the study. This is not surprising, because up until now human gene therapy has failed for the most part to progress beyond the clinical testing stage. However, there is great hope that ultimately gene therapy will prove a powerful new form of treatment, and when that occurs it could result in a new category of human gene patent litigation. It is important to bear in mind that the mere perception of a threat of litigation could alter the course of research and the commercialization of biomedical technology, so it would be a mistake to assume that litigation tells the whole story on the impact of human gene patents. But perceived threats could be overblown, and litigation does provide some a publicly accessible source data from which to objective assess the effect of these patents on innovation. The high degree of concern that has been expressed regarding the perceived detrimental impact of human gene patents on research and medicine is not reflected in the litigation history of these patents. To date, these patents do not appear to have been enforced in a manner that would warrant enactment of legislation to ban the patenting of DNA and DNA-based inventions. Many of the attacks on gene patents assume that the overall cost of these patents to society exceeds any positive benefit. However, the critics often fail to account for the positive benefits of human gene patents, particularly in the protection of therapeutic proteins, but perhaps even in incentivizing the discovery and commercialization of research tools and genetic diagnostics. Any appraisal of the patent system that focuses solely on the patents right to exclude will naturally lead to a conclusion that patents are a detriment to society, but such an analysis is flawed for failing to account for the substantial benefits to be derived from the patents ability to incentivize research and innovation. The newest and next frontier in the battle against doping in sports targets gene doping Gene therapy is a nascent medical field that refers to the insertion of a new gene - a functional one - into human cells to correct the DNA for some defective, malfunctioning, or absent gene This can be facilitated by introducing a virus into the cells through injection or delivery to the lungs by aerosol. Sometimes, cells are removed from the body, treated outside the body in a lab, and then reintroduced into the body. Gene therapy has shown promise in patients with immuno-deficiencies or hemophili Researchers are developing pharmaceuticals that can switch on the genes responsible for protein synthesis as well.
author2 黃承啟
author_facet 黃承啟
CHEN,YUNG-CHEN
陳永震
author CHEN,YUNG-CHEN
陳永震
spellingShingle CHEN,YUNG-CHEN
陳永震
A Study on the Regulation of Gene Therapy
author_sort CHEN,YUNG-CHEN
title A Study on the Regulation of Gene Therapy
title_short A Study on the Regulation of Gene Therapy
title_full A Study on the Regulation of Gene Therapy
title_fullStr A Study on the Regulation of Gene Therapy
title_full_unstemmed A Study on the Regulation of Gene Therapy
title_sort study on the regulation of gene therapy
publishDate 2011
url http://ndltd.ncl.edu.tw/handle/47040743005884790016
work_keys_str_mv AT chenyungchen astudyontheregulationofgenetherapy
AT chényǒngzhèn astudyontheregulationofgenetherapy
AT chenyungchen jīyīnzhìliáofǎzhìhuàzhīyánjiū
AT chényǒngzhèn jīyīnzhìliáofǎzhìhuàzhīyánjiū
AT chenyungchen studyontheregulationofgenetherapy
AT chényǒngzhèn studyontheregulationofgenetherapy
_version_ 1718051337619374080